Volume | 33,611 |
|
|||||
News | - | ||||||
Day High | 28.14 | Low High |
|||||
Day Low | 27.26 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Stevanato Group SpA | STVN | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
27.26 | 27.26 | 28.14 | 27.42 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
561 | 33,611 | US$ 27.65 | US$ 929,289 | - | 23.00 - 36.30 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
09:26:32 | 7 | US$ 28.095 | USD |
Stevanato Group SpA Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
8.15B | 295.54M | - | 1B | 142.85M | 0.48 | 57.02 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Stevanato News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STVN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 26.61 | 28.19 | 26.4708 | 27.44 | 346,602 | 1.48 | 5.56% |
1 Month | 31.495 | 31.61 | 26.4708 | 28.49 | 349,894 | -3.41 | -10.81% |
3 Months | 34.51 | 34.73 | 25.52 | 30.27 | 395,934 | -6.42 | -18.60% |
6 Months | 28.98 | 34.73 | 23.00 | 29.10 | 340,347 | -0.89 | -3.07% |
1 Year | 26.68 | 36.30 | 23.00 | 29.77 | 331,738 | 1.41 | 5.28% |
3 Years | 16.65 | 36.30 | 13.355 | 23.11 | 360,741 | 11.44 | 68.71% |
5 Years | 16.65 | 36.30 | 13.355 | 23.11 | 360,741 | 11.44 | 68.71% |
Stevanato Description
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America. |